What is the first-line treatment for Ulcerative Colitis (UC) in adolescents?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The first-line treatment for Ulcerative Colitis (UC) in adolescents is oral and rectal 5-aminosalicylate (5-ASA) therapy.

Treatment Overview

  • For mild to moderate UC, 5-ASA is recommended as first-line therapy to induce symptomatic remission, with a dosage of 1 g daily for rectal 5-ASA and at least 1 g daily for 5-ASA enemas 1.
  • The goal of therapy is complete remission, defined as both symptomatic and endoscopic remission without corticosteroid therapy 1.
  • Corticosteroids are recommended as second-line therapy for patients who fail to respond to 5-ASA therapy, with a commonly used regimen of oral prednisone 40 to 60 mg/day (or equivalent) 1.

Key Considerations

  • 5-ASA has been shown to be effective in inducing symptomatic and endoscopic remission in patients with mild to moderate active UC, with a pooled odds ratio for symptomatic remission of 8.30 and for endoscopic remission of 5.31 1.
  • Corticosteroids have been shown to be superior to placebo for induction of remission, with a relative risk of no remission of 0.65 1.
  • The optimal dose and dosing regimen for systemic corticosteroids in UC is uncertain, but oral prednisone 40 to 60 mg/day is a commonly used regimen 1.

From the Research

First-Line Treatment for Ulcerative Colitis (UC) in Adolescents

  • The first-line treatment for adolescents with UC includes salicylates, such as mesalazine or sulphasalazine 2.
  • According to a study published in 2012, oral 5-aminosalicylates (5-ASAs) are recommended as first-line therapy in patients with mild to moderate UC 3.
  • Another study published in 2016 states that mesalamine is the first-line treatment in patients with mild to moderate UC 4.
  • Corticosteroids, such as prednisolone, may also be used as first-line treatment, but their use is often limited due to potential adverse effects on growth and development in children and adolescents 2, 5.
  • More recently, subcutaneous anti-TNF medication, such as adalimumab, has been considered as an alternative first-line therapy for pediatric UC 6.

Treatment Options

  • Mesalazine or sulphasalazine are commonly used as first-line medications for UC in adolescents 2.
  • Corticosteroids, such as prednisolone, may be used in combination with other medications or as an alternative to first-line medications 2, 5.
  • Anti-TNF drugs, such as infliximab, adalimumab, and golimumab, may be used for more severe or refractory cases of UC 4.
  • Vedolizumab, a drug directed against the integrins α4β7, has been shown to be effective for the induction and maintenance of remission in moderate-to-severe UC patients 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.